Tordera R, Pei Q, Newson M, Gray K, Sprakes M, Sharp T
University Department of Pharmacology, Mansfield Road, Oxford OX1 3QT, UK.
Neuropharmacology. 2003 Jun;44(7):893-902. doi: 10.1016/s0028-3908(03)00096-0.
Selective 5-HT(1A) receptor antagonists enhance the effect of selective serotonin reuptake inhibitors (SSRIs) on presynaptic 5-HT function, and have potential as antidepressant augmentation therapies. The present study tested the effect of different selective 5-HT(1A) receptor antagonists (WAY 100635, NAD-299, p-MPPI and LY 426965) in combination with a SSRI (paroxetine), on postsynaptic 5-HT function measured by increased expression of the immediate early gene, Arc. Paroxetine (5 mg/kg s.c.) combined with WAY 100635 (0.3 mg/kg s.c.) increased Arc mRNA in frontal, parietal and piriform cortices, and caudate putamen. Paroxetine (5 mg/kg s.c.) plus NAD-299 (1 or 5 mg/kg s.c.) had a similar effect. None of these drugs increased Arc mRNA when administered alone. Paroxetine (5 mg/kg s.c.) plus p-MPPI (8.5 mg/kg s.c.) also increased Arc mRNA but p-MPPI itself elevated Arc mRNA in many regions. Whilst LY 426965 (3 or 10 mg/kg s.c.) had no effect alone, when combined with paroxetine (5 mg/kg s.c.), the drug increased Arc mRNA in caudate putamen but not cortical regions.In conclusion, this study demonstrates that four 5-HT(1A) receptor antagonists augment the effect of an SSRI on Arc mRNA expression, which is suggestive of increased postsynaptic 5-HT function. However, the data reveal certain differences in the 5-HT(1A) receptor antagonists not recognised in models of presynaptic 5-HT function.
选择性5-羟色胺(5-HT)1A受体拮抗剂可增强选择性5-羟色胺再摄取抑制剂(SSRI)对突触前5-羟色胺功能的作用,具有作为抗抑郁增效疗法的潜力。本研究测试了不同的选择性5-HT1A受体拮抗剂(WAY 100635、NAD-299、p-MPPI和LY 426965)与一种SSRI(帕罗西汀)联合使用时,对通过即刻早期基因Arc表达增加所测量的突触后5-羟色胺功能的影响。帕罗西汀(5毫克/千克皮下注射)与WAY 100635(0.3毫克/千克皮下注射)联合使用可增加额叶、顶叶、梨状皮质以及尾状壳核中的Arc mRNA。帕罗西汀(5毫克/千克皮下注射)加NAD-299(1或5毫克/千克皮下注射)有类似效果。这些药物单独使用时均未增加Arc mRNA。帕罗西汀(5毫克/千克皮下注射)加p-MPPI(8.5毫克/千克皮下注射)也增加了Arc mRNA,但p-MPPI本身在许多区域升高了Arc mRNA。虽然LY 426965(3或10毫克/千克皮下注射)单独使用时无作用,但与帕罗西汀(5毫克/千克皮下注射)联合使用时,该药物增加了尾状壳核中的Arc mRNA,但未增加皮质区域的Arc mRNA。总之,本研究表明,四种5-HT1A受体拮抗剂增强了SSRI对Arc mRNA表达的作用,这提示突触后5-羟色胺功能增强。然而,数据显示在突触前5-羟色胺功能模型中未被认识到的5-HT1A受体拮抗剂之间存在某些差异。